Relafen 750, structurally known as naproxen, represents a important case study from a pharmaceutical pharmacy standpoint. This exhibits its therapeutic effect primarily by reducing the activity of cyclooxygenase (COX) enzymes, specifically COX-2, thereby limiting prostaglandin synthesis . The selective inhibition of COX-2, compared to traditional N